moxifloxacin has been researched along with Dihydrotanshinone I in 1 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (Dihydrotanshinone I) | Trials (Dihydrotanshinone I) | Recent Studies (post-2010) (Dihydrotanshinone I) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 88 | 0 | 74 |
| Protein | Taxonomy | moxifloxacin (IC50) | Dihydrotanshinone I (IC50) |
|---|---|---|---|
| Replicase polyprotein 1a | Severe acute respiratory syndrome-related coronavirus | 3.05 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 0.59 | |
| Acetylcholinesterase | Homo sapiens (human) | 1 | |
| Tyrosine-protein phosphatase non-receptor type 6 | Homo sapiens (human) | 3.67 | |
| Tyrosine-protein phosphatase non-receptor type 11 | Homo sapiens (human) | 3.94 | |
| ELAV-like protein 1 | Homo sapiens (human) | 0.1085 | |
| Hypoxia-inducible factor 1-alpha | Homo sapiens (human) | 2.17 | |
| Endothelial PAS domain-containing protein 1 | Homo sapiens (human) | 2.17 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; Gao, K; Huang, F; Tepe, JJ; Wang, R; Wei, GW | 1 |
1 other study(ies) available for moxifloxacin and Dihydrotanshinone I
| Article | Year |
|---|---|
Perspectives on SARS-CoV-2 Main Protease Inhibitors.
Topics: Antiviral Agents; Coronavirus 3C Proteases; Humans; Protease Inhibitors | 2021 |